Skip to main content
OpenTrials
Completed

NCT Number: NCT00660803

Retrospective Brazilian Study of Fulvestrant in Advanced Breast Cancer

Characterize the demographic and clinical features, as well as the main treatment results, among patients with advanced breast cancer treated with fulvestrant in Brazil.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Breast Cancer Breast Diseases Breast Neoplasms Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

Research Site, Recife, Pernambuco, Brazil

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Positive HR or ER by immunohistochemistry
  • Postmenopausal status at the time of treatment with fulvestrant
  • Failure of at least one previous endocrine therapy before treatment with fulvestrant.

Exclusion criteria

  • Patients who are still undergoing treatment with fulvestrant will not be eligible to participate in the study

Treatment and study plan

Fulvestrant

Drug

Other names: Faslodex

Primary outcomes

  1. Time to tumour progression

  2. Objective response

Secondary outcomes

  1. Duration of treatment with fulvestrant

  2. Time and duration of response

  3. Overall survival

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Collaborators

  • Dendrix - Scientific Information Architecture

Registry information

Important dates

Study start
2008
Primary completion
2009
Study completion
2009
First posted
Apr 17, 2008
Registry last updated
Jan 21, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.